Prot# RPC01-3204: A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Serverely Active Crohn's Disease

Project: Research project

Project Details

StatusActive
Effective start/end date9/9/199/9/22

Funding

  • ICON Clinical Research, LLC (Prot# RPC01-3204)
  • Celgene International II Sàrl (Prot# RPC01-3204)